These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7833497)

  • 21. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyruvate dehydrogenase activity is stimulated by growth hormone (GH) in human mononuclear cells: a new tool to measure GH responsiveness in man.
    Clot JP; Benelli C; Fouque F; Bernard R; Durand D; Postel-Vinay MC
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1258-62. PubMed ID: 1592868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
    Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiency of pyruvate dehydrogenase activity in pancreatic islets of diabetic GK rats.
    Zhou YP; Ostenson CG; Ling ZC; Grill V
    Endocrinology; 1995 Aug; 136(8):3546-51. PubMed ID: 7628391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
    Desfaits AC; Serri O; Renier G
    Diabetes Care; 1998 Apr; 21(4):487-93. PubMed ID: 9571329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study.
    Vestergaard H; Weinreb JE; Rosen AS; Bjørbaek C; Hansen L; Pedersen O; Kahn BB
    J Clin Endocrinol Metab; 1995 Jan; 80(1):270-5. PubMed ID: 7829624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gliclazide: metabolic and vascular effects--a perspective.
    Alberti KG; Johnson AB; Taylor R
    Metabolism; 1992 May; 41(5 Suppl 1):40-5. PubMed ID: 1574015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Am J Med; 1991 Jun; 90(6A):37S-45S. PubMed ID: 1872303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemobiological properties of gliclazide.
    Ziegler O; Drouin P
    J Diabetes Complications; 1994; 8(4):235-9. PubMed ID: 7833500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
    Serradas P; Bailbé D; Portha B
    Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gliclazide and insulin action in human muscle.
    Bak JF; Pedersen O
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S61-4. PubMed ID: 1794267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study.
    Mailhot J
    Clin Ther; 1993; 15(6):1060-8. PubMed ID: 8111803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte ecto-5'-nucleotidase in obese type 2 diabetic patients treated with gliclazide.
    Stefanovic V; Antic S; Milojkovic M; Lazarević G; Vlahovic P
    Diabetes Metab; 2006 Apr; 32(2):166-70. PubMed ID: 16735966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients.
    Bak JF; Schmitz O; Sørensen NS; Pedersen O
    Diabetes; 1989 Nov; 38(11):1343-50. PubMed ID: 2559864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasting hyperglycemia normalizes oxidative and nonoxidative pathways of insulin-stimulated glucose metabolism in noninsulin-dependent diabetes mellitus.
    Mandarino LJ; Consoli A; Kelley DE; Reilly JJ; Nurjhan N
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1544-51. PubMed ID: 2121778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyruvate dehydrogenase activation by insulin in human circulating lymphocytes and the possible pathway involved.
    Curto M; Piccinini M; Marino C; Mostert M; Bruno R; Rinaudo MT
    Int J Biochem; 1990; 22(1):99-106. PubMed ID: 2184057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dysfunction of insulin mediator protein kinase FA in lymphocytes of patients with NIDDM.
    Yang SD; Hwang HS; Ha TL; Lai YG; Jean YJ
    Diabetes; 1992 Jan; 41(1):68-75. PubMed ID: 1309356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
    Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
    Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of NIDDM in the decade of the 90s.
    Krall LP
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S15-9. PubMed ID: 1794261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.